Johnson & Johnson (JNJ) Downgraded by Vetr to “Hold”

Johnson & Johnson (NYSE:JNJ) was downgraded by Vetr from a “buy” rating to a “hold” rating in a research note issued on Monday, January 8th. They presently have a $147.40 target price on the stock. Vetr‘s target price indicates a potential upside of 5.88% from the company’s previous close.

Several other equities analysts have also recently issued reports on the company. Cowen reaffirmed an “outperform” rating and set a $155.00 price objective (up from $147.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Jefferies Group boosted their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Finally, Barclays boosted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $146.16.

Johnson & Johnson (JNJ) traded up $1.03 during trading hours on Monday, reaching $139.22. The company had a trading volume of 3,127,367 shares, compared to its average volume of 7,813,488. Johnson & Johnson has a 12-month low of $112.62 and a 12-month high of $148.32. The stock has a market cap of $371,250.00, a P/E ratio of 356.72, a PEG ratio of 2.55 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The company’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the business posted $1.58 EPS. equities research analysts predict that Johnson & Johnson will post 8.11 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of JNJ. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson during the second quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. raised its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares in the last quarter. IHT Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after acquiring an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson during the second quarter worth $124,000. 65.79% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was first posted by BBNS and is owned by of BBNS. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/johnson-johnson-jnj-lowered-to-hold-at-vetr/1821636.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.